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Alzheimer’sdisease (AD)is themost frequentneurodegener-
ative disease in the elderly. It is characterized by progressive
impairment in multiple cognitive domains, in particular
memory, leading to severe impairment in daily living
followedbyprogressivephysicaldeteriorationanddeath.The
neuropathological hallmark of AD is the presence of cortical
intracellular neuroﬁbrillary tangles (NFT) and extracellular
β-amyloid (Aβ) plaques, which leads to synapse dysfunction,
neuronal cell loss, and subsequent brain atrophy. In the
past few decades the knowledge of the key pathogenic
mechanisms of the disease has improved, but it remains
far from being fully understood. Traditionally, the diagnosis
of AD has been based on clinical symptoms, and accuracy
studies of the current clinical criteria conducted in referral
have shown high sensitivity for AD. However, identiﬁcation
of the disease, in particular in the early stages, remains
diﬃcult as pathological alterations may be apparent several
years before the clear-cut clinical picture.
There is growing evidence that the use of biomarkers
will increase our ability to identify AD earlier in the disease
process and with higher accuracy. In addition, biomarkers
will help elucidate the underlying biological and molecular
changes, improve the detection of patients suitable for spe-
ciﬁc treatments, research studies or drug trials, and will con-
tribute to a better management of the disease in the clinical
practice. In this special issue on early clinical and molecular
detectionofAD,wehaveinvitedmanuscriptsthatspeciﬁcally
address issues related to early and improved diagnosis of AD.
The ﬁrst two articles address the usefulness of current
biological and neuroimaging markers for the diagnosis
of AD, including genetic variation, plasma, serum and
CSF biomarkers, brain atrophy measures, functional MRI
measures, and amyloid burden evaluated by PiB compound.
The third paper reevaluates the usefulness of common
clinical rating scales for AD, frontotemporal dementia, and
vascular dementia using factor analysis. In the fourth paper,
the sociocultural impacts of novel molecular technologies
for the early diagnosis of AD are addressed. The paper
outlines three steps to assess sociocultural impacts. First,
conceptual analysis of the ideas underlying technological
developments shows how these technologies redraw the
boundary between AD and normal ageing and between
biological and social approaches of ageing. Second, scenarios
are designed depicting diﬀerent possible futures of AD
diagnosis and societal ways to deal with ageing. Finally,
the paper reviews the possibilities for deliberation on the
potential sociocultural impacts.
Manuscripts ﬁve and six are original research studies
assessing the eﬀect of speciﬁc genetic variations on AD and
AD endophenotypes. While the study by Swaminathan et al.
explores the eﬀe c to fc o p yn u m b e rv a r i a t i o n( C N V )d e r i v e d
by genome-wide screening in the ADNI cohort on AD and
MCI, the study by Tedde et al. explores the eﬀect of genetic
variation in CDKN2A and CDKN2B on AD. Finally, the
last paper assesses the eﬀect of siRNAs silencing on gene
expression. While commonly studies use RNA interference
(RNAi) to investigate the eﬀect of silencing of speciﬁc genes
ontheirexpressionandeﬀectoncellmetabolism,thecurrent
paper takes this technology further by assessing the eﬀect of
allele-speciﬁc silencing of a particular mutant allele, in this
case mutation L392V in PSEN1.
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